Stockreport

Novo Nordisk's next-gen obesity drug CagriSema achieves lower weight loss than expected [Yahoo! Finance]

Eli Lilly and Company  (LLY) 
Last eli lilly and company earnings: 4/23 06:25 am Check Earnings Report
US:NYSE Investor Relations: investor.lilly.com
PDF obesity drug CagriSema helped overweight patients cut their weight by 22.7% in a late-stage trial, below the 25% it had expected, sending its shares down sharply. The [Read more]